Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
ALS Drug Promise | Athira Pharma's ATH-1105 shows potential in ALS treatment, with positive preclinical data and Phase 1 results driving future clinical plans |
Financial Crossroads | Despite $37M cash reserves, Athira faces financial challenges. Market cap decline to $9.8M reflects investor caution amid strategic shifts |
Strategic Pivot | Explore Athira's strategic review process and pursuit of partnerships to accelerate ATH-1105 development and enhance shareholder value |
Market Sentiment | Analyst ratings hold at "Market Perform" without price targets, reflecting cautious optimism as Athira advances its focused ALS program |
Metrics to compare | ATHA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATHAPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −4.2x | −0.5x | |
PEG Ratio | −0.01 | 0.10 | 0.00 | |
Price/Book | 0.5x | 2.7x | 2.6x | |
Price / LTM Sales | - | 1.7x | 3.3x | |
Upside (Analyst Target) | −0.2% | 93.4% | 40.3% | |
Fair Value Upside | Unlock | −9.2% | 5.1% | Unlock |